top of page

RadTox Provides
personalized monitoring for treatment effectiveness

By comparing conditions before treatment, after treatment, and even during long-term surveillance in the recovery phase



The most common cancer treatment monitoring tool is imaging, including CT scans, MRI, PET scans, and ultrasound. They are performed every 3 to 4 months after treatment to monitor size, shape, and metabolic activity changes. Changes observed on these scans can indicate whether the treatment is effective.

These traditional tools are effective but may not reveal the true treatment response due to their sensitivity. Additionally, the long intervals (3-4 months) could lead to missed or delayed next-step treatments.


Tumor Biomarkers

Other commonly used tools include tumor biomarkers such as CEA (carcinoembryonic antigen) or CA (cancer antigen).


These biomarkers aid in monitoring and can even assist in cancer diagnosis. However, they often have low sensitivity, potentially missing cancer cases, and are typically more specific to certain cancer types, limiting their universal monitoring application.

RadTox™ cfDNA Test

Modern treatment methods, including liquid biopsy, have gained traction for monitoring cancer treatment responses. Liquid biopsy relies on components monitored in body fluids, especially blood, and tells the cancer treatment responses based on the presence or change of these components. One of the liquid biopsy biomarkers is the total cfDNA (cell-free DNA) level. Since the level of cfDNA increases over cancer progression and increases when poor survival or prognosis appears, these changes can be monitored during and after treatment to tell doctors if the treatment is effective.

RadTox™ test quantifies the total cfDNA level and provides personalized treatment efficacy information by comparing the conditions of before-treatment, post-treatment, and even long-term surveillance monitoring during the recovery stage.


Talk to your oncologists about the RadTox™ test


RadTox™ test only needs a small amount of blood and can be performed frequently for monitoring the condition changes. The test's serial monitoring and short turnaround time (less than a week) allow real-time monitoring that other monitoring tools can’t achieve.


Since the RadTox™ test just got covered by Medicare starting Jan. 1, 2024. Your doctors may not know the existence of the test. You can discuss your cancer treatment monitoring plan with your physicians and ask for the addition of this new test. We also diligently work with other private/commercial insurers to make reimbursement possible. DiaCarta offers a Patient Financial Assistance Program to make RadTox available to all patients. No surprise billing for tests not covered by your health insurance plan. Please inquire at if you are eligible to receive financial assistance.

About the RadTox™ test

The RadTox™ test is not an FDA-approved test. It is a laboratory-developed test (LDT) performed at DiaCarta’s CLIA-certified and CAP-accredited clinical lab based in Pleasanton, California. The test is only available on your physician’s order. Once the test is ordered, a blood sample collection package will be available through the physician free of charge. The report will be available through your physician within 5 to 7 days after receiving your samples.


Thanks for submitting!

bottom of page